Penumbra Stockholders Approve $14.5 Billion Merger with Boston Scientific
PEN sits 46% above its 52-week low of $221.26.
Summary
Penumbra stockholders have approved the merger agreement with Boston Scientific, a key step towards completing the previously announced $14.5 billion acquisition.
Key Events · M&A and Partnerships · PEN
-
Merger Proposal Approved
Stockholders voted to adopt the Agreement and Plan of Merger with Boston Scientific Corporation, with 28,564,786 votes for and 85,334 against.
-
Key Condition Met
This approval satisfies a crucial condition for the consummation of the $14.5 billion acquisition, which was previously disclosed in the Q1 2026 earnings report.
-
Remaining Conditions
The merger is still subject to other closing conditions, including the expiration or termination of waiting periods under antitrust laws and receipt of non-U.S. regulatory clearances.
Analysis · PEN · Industrial Applications And Services
Penumbra's stockholders have overwhelmingly approved the Agreement and Plan of Merger with Boston Scientific Corporation. This vote satisfies a critical condition for the previously announced $14.5 billion acquisition, significantly advancing the transaction towards completion and reducing uncertainty. The merger, which is larger than Penumbra's current market capitalization, remains subject to other closing conditions, including regulatory antitrust and foreign investment approvals.
At the time of this filing, PEN was trading at $323.86 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.7B. The 52-week trading range was $221.26 to $362.41. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.